JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105
JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.
Read original at benzingaStocks · News reference
Edwards Lifesciences Sees Q3 Adj EPS $0.71-$0.77 vs $0.74 Est; Sees Sales $1.630B-$1.710B vs $1.689B Est
Edwards Lifesciences (NYSE:EW) is looking for Q3 Adj EPS of $0.71-$0.77 vs $0.74 analyst estimate. sees sales of $1.630 billion-$1.710 billion vs $1.689 billion analyst estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 8:16 PM
- Checked
- Jul 23, 2026, 8:16 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101
Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.
Read original at benzingaEdwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says
Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.
Read original at benzingaEdwards Lifesciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
Read original at benzinga